State Of New Jersey Common Pension Fund D Nektar Therapeutics Transaction History

State Of New Jersey Common Pension Fund D

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 28, 2022	SELL	$3.04 - $5.14 $211,541 - $357,672	-69,586 Reduced 11.89%	515,907 $1.65 Million
Q2 2022 Aug 04, 2022	BUY	$3.17 - $6.17 $1.1 Million - $2.14 Million	347,474 Added 145.99%	585,493 $2.23 Million
Q4 2021 Jan 31, 2022	BUY	$10.83 - $18.41 $396,139 - $673,400	36,578 Added 18.16%	238,019 $3.22 Million
Q3 2021 Oct 27, 2021	BUY	$13.07 - $18.84 $840,440 - $1.21 Million	64,303 Added 46.89%	201,441 $3.62 Million
Q2 2021 Jul 23, 2021	BUY	$16.52 - $20.4 $342,195 - $422,565	20,714 Added 17.79%	137,138 $2.35 Million
Q1 2021 Apr 27, 2021	SELL	$16.56 - $25.46 $171,462 - $263,612	-10,354 Reduced 8.17%	116,424 $2.33 Million
Q4 2020 Feb 03, 2021	BUY	$15.77 - $19.03 $18,592 - $22,436	1,179 Added 0.94%	126,778 $2.16 Million
Q3 2020 Oct 27, 2020	BUY	$16.59 - $24.79 $77,740 - $116,165	4,686 Added 3.88%	125,599 $2.08 Million
Q2 2020 Aug 04, 2020	SELL	$16.86 - $23.44 $107,297 - $149,172	-6,364 Reduced 5.0%	120,913 $2.8 Million
Q4 2019 Jan 31, 2020	SELL	$15.87 - $23.12 $95,585 - $139,251	-6,023 Reduced 4.52%	127,277 $2.75 Million
Q3 2019 Oct 23, 2019	SELL	$16.91 - $36.27 $6.88 Million - $14.8 Million	-406,700 Reduced 75.31%	133,300 $2.43 Million
Q1 2019 May 02, 2019	BUY	$31.58 - $46.35 $473,700 - $695,250	15,000 Added 2.86%	540,000 $18.1 Million
Q4 2018 Jan 25, 2019	BUY	$30.43 - $56.65 $12.8 Million - $23.8 Million	420,000 Added 400.0%	525,000 $17.3 Million
Q3 2017 Oct 25, 2017	BUY	$17.79 - $24.0 $1.87 Million - $2.52 Million	105,000	105,000 $2.52 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $152M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.